Work

Pilot Study of Thrice-Weekly Low-Dose Rituximab (RTX) in Chronic Lymphocytic Leukemia (CLL): Decreased CD20 Loss Via “Shaving” and a Novel Strategy for Enhanced Therapeutic Targeting.

Year: 2005

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v106.11.2970.2970

Authors: Michael E. Williams, John J. Densmore, Andrew W. Pawluczkowycz, Paul V. Beum, Adam D. Kennedy, Margaret A. Lindorfer, Susan H. Hamil, Gina R. Petroni, Jane C. Eggleton, Ronald P. Taylor

Institution: University of Virginia

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2556398071

FWCI:

Cites:

Cited by:

Related to: 10